CYP17 inhibitors for prostate cancer therapy

Journal of Steroid Biochemistry and Molecular Biology

Volumn 125, Issue 1-2, 2011, Pages 23-31

  Vasaitis, Tadas S ^c,d   Bruno, Robert D ^e   Njar, Vincent C O ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND EASTERN SHORE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Abiraterone acetate; CYP17; Inhibition of androgen synthesis; Inhibitors of CYP17; Ketoconazole; PC treatment; Prostate cancer (PC); TAK 700; VN 124 1 (TOK 001)

Indexed keywords

17 HYDROXYPREGNENOLONE; ABIRATERONE ACETATE; ALDOSTERONE; ANDROSTANOLONE; ANDROSTENEDIONE; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CHOLESTEROL; CORTICOSTERONE; DEXAMETHASONE; DOCETAXEL; EVEROLIMUS; GEFITINIB; HYDROCORTISONE; HYDROXYPROGESTERONE; KETOCONAZOLE; ORTERONEL; PRASTERONE; PREDNISONE; PREGNENOLONE; PROGESTERONE; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE; TESTOSTERONE; TOK 001; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ANDROGEN SYNTHESIS; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER THERAPY; DISEASE COURSE; DRUG EXPOSURE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; FATIGUE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; IC 50; LIVER TOXICITY; NAUSEA; NONHUMAN; PROSTATE CANCER; REVIEW; SINGLE DRUG DOSE; STEROIDOGENESIS; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE;

ANDROGENS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; ENZYME INHIBITORS; HUMANS; MALE; MOLECULAR STRUCTURE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79956132010     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.11.005     Document Type: Review

References (91)

1. American Cancer Society Facts and Figures 2009 2009
2. L.J. Denis, and K. Griffiths Endocrine treatment in prostate cancer Semin. Surg. Oncol. 18 1 2000 52 74 (Pubitemid 30036120)
3. J.L. Mohler, C.W. Gregory, O.H. Ford 3rd., D. Kim, C.M. Weaver, P. Petrusz, E.M. Wilson, and F.S. French The androgen axis in recurrent prostate cancer Clin. Cancer Res. 10 2 2004 440 448 (Pubitemid 38173980)
4. W.B. Pratt, and D.O. Toft Steroid receptor interactions with heat shock protein and immunophilin chaperones Endocr. Rev. 18 3 1997 306 360 (Pubitemid 27246880)
5. B.J. Feldman, and D. Feldman The development of androgen-independent prostate cancer Nat. Rev. Cancer 1 1 2001 34 45 (Pubitemid 33741879)
6. A.M. Velasco, K.A. Gillis, Y. Li, E.L. Brown, T.M. Sadler, M. Achilleos, L.M. Greenberger, P. Frost, W. Bai, and Y. Zhang Identification and validation of novel androgen-regulated genes in prostate cancer Endocrinology 145 8 2004 3913 3924 (Pubitemid 39037580)
7. J.T. Isaacs Role of androgens in prostatic cancer Vitam. Horm. 49 1994 433 502
8. B. Chatterjee The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer Mol. Cell. Biochem. 253 1-2 2003 89 101 (Pubitemid 37321715)
9. F. Labrie, L. Cusan, J.L. Gomez, C. Martel, R. Berube, P. Belanger, A. Belanger, L. Vandenput, D. Mellstrom, and C. Ohlsson Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer J. Steroid Biochem. Mol. Biol. 113 1-2 2009 52 56
10. M. Stanbrough, G.J. Bubley, K. Ross, T.R. Golub, M.A. Rubin, T.M. Penning, P.G. Febbo, and S.P. Balk Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res. 66 5 2006 2815 2825
11. H. Suzuki, K. Okihara, H. Miyake, M. Fujisawa, S. Miyoshi, T. Matsumoto, M. Fujii, Y. Takihana, T. Usui, T. Matsuda, S. Ozono, H. Kumon, T. Ichikawa, and T. Miki Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade J. Urol. 180 3 2008 921 927
12. J. Morote, A. Orsola, J. Planas, E. Trilla, C.X. Raventos, L. Cecchini, and R. Catalan Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J. Urol. 178 4 Pt 1 2007 1290 1295 (Pubitemid 47368393)
13. M.G. Oefelein, A. Feng, M.J. Scolieri, D. Ricchiutti, and M.I. Resnick Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making Urology 56 6 2000 1021 1024
14. T. Tammela Endocrine treatment of prostate cancer J. Steroid Biochem. Mol. Biol. 92 4 2004 287 295 (Pubitemid 40128250)
15. T. Nishiyama, Y. Hashimoto, and K. Takahashi The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer Clin. Cancer Res. 10 21 2004 7121 7126 (Pubitemid 39487695)
16. J. Geller, J.D. Albert, D.A. Nachtsheim, and D. Loza Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy J. Urol. 132 4 1984 693 696 (Pubitemid 14017006)
17. E.A. Mostaghel, S.T. Page, D.W. Lin, L. Fazli, I.M. Coleman, L.D. True, B. Knudsen, D.L. Hess, C.C. Nelson, A.M. Matsumoto, W.J. Bremner, M.E. Gleave, and P.S. Nelson Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer Cancer Res. 67 10 2007 5033 5041 (Pubitemid 46910214)
18. L.S. Marks, E.A. Mostaghel, and P.S. Nelson Prostate tissue androgens: history and current clinical relevance Urology 72 2 2008 247 254
19. J. Holzbeierlein, P. Lal, E. LaTulippe, A. Smith, J. Satagopan, L. Zhang, C. Ryan, S. Smith, H. Scher, P. Scardino, V. Reuter, and W.L. Gerald Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance Am. J. Pathol. 164 1 2004 217 227 (Pubitemid 38364606)
20. Y.P. Yu, D. Landsittel, L. Jing, J. Nelson, B. Ren, L. Liu, C. McDonald, R. Thomas, R. Dhir, S. Finkelstein, G. Michalopoulos, M. Becich, and J.H. Luo Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy J. Clin. Oncol. 22 14 2004 2790 2799 (Pubitemid 41079896)
21. C.D. Chen, D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, R. Vessella, M.G. Rosenfeld, and C.L. Sawyers Molecular determinants of resistance to antiandrogen therapy Nat. Med. 10 1 2004 33 39 (Pubitemid 38524696)
22. J.D. Debes, and D.J. Tindall Mechanisms of androgen-refractory prostate cancer N. Engl. J. Med. 351 15 2004 1488 1490 (Pubitemid 39315314)
23. J. Picado-Leonard, and W.L. Miller Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21 DNA (Mary Ann Liebert, Inc.) 6 5 1987 439 448 (Pubitemid 18085844)
24. M.K. Akhtar, S.L. Kelly, and M.A. Kaderbhai Cytochrome b(5) modulation of 17α hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis J. Endocrinol. 187 2 2005 267 274 (Pubitemid 41685186)
25. 5 in the biosynthesis of androgens by human P450c17 Arch. Biochem. Biophys. 317 2 1995 343 347
26. P. Lee-Robichaud, A.Z. Shyadehi, J.N. Wright, M.E. Akhtar, and M. Akhtar Mechanistic kinship between hydroxylation and desaturation reactions: acyl-carbon bond cleavage promoted by pig and human CYP17 (P-450(17)alpha; 17 alpha-hydroxylase-17,20-lyase) Biochemistry 34 43 1995 14104 14113
27. 5 in androgen-synthesizing tissues of the human Biol. Reprod. 71 1 2004 83 88 (Pubitemid 38915312)
28. B.J. Brock, and M.R. Waterman Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species Biochemistry 38 5 1999 1598 1606
29. H.R. Fevold, M.C. Lorence, J.L. McCarthy, J.M. Trant, M. Kagimoto, M.R. Waterman, and J.I. Mason Rat P450(17 alpha) from testis: characterization of a full-length cDNA encoding a unique steroid hydroxylase capable of catalyzing both delta 4- and delta 5-steroid-17,20-lyase reactions Mol. Endocrinol. 3 6 1989 968 975 (Pubitemid 19168587)
30. S. Nakajin, M. Shinoda, M. Haniu, J.E. Shively, and P.F. Hall C21 steroid side chain cleavage enzyme from porcine adrenal microsomes. Purification and characterization of the 17 alpha-hydroxylase/C17,20-lyase cytochrome P-450 J. Biol. Chem. 259 6 1984 3971 3976 (Pubitemid 14170114)
31. N. Sakai, M. Tanaka, S. Adachi, W.L. Miller, and Y. Nagahama Rainbow trout cytochrome P-450c17 (17 alpha-hydroxylase/17,20-lyase). cDNA cloning, enzymatic properties and temporal pattern of ovarian P-450c17 mRNA expression during oogenesis FEBS Lett. 301 1 1992 60 64
32. R.J. Auchus The backdoor pathway to dihydrotestosterone Trends Endocrinol. Metab. 15 9 2004 432 438 (Pubitemid 39440726)
33. S.W. Lamberts, P. Uitterlinden, and F.H. de Jong Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue Cancer Res. 48 21 1988 6063 6068 (Pubitemid 18266802)
34. M.E. Keller-Wood, and M.F. Dallman Corticosteroid inhibition of ACTH secretion Endocr. Rev. 5 1 1984 1 24
35. G. Attard, A.H. Reid, D. Olmos, and J.S. de Bono Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven Cancer Res. 69 12 2009 4937 4940
36. R.J. Auchus Overview of dehydroepiandrosterone biosynthesis Semin. Reprod. Med. 22 4 2004 281 288 (Pubitemid 40030078)
37. C.J. Ryan, M.R. Smith, L. Fong, J.E. Rosenberg, P. Kantoff, F. Raynaud, V. Martins, G. Lee, T. Kheoh, J. Kim, A. Molina, and E.J. Small Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J. Clin. Oncol. 28 9 2010 1481 1488
38. D.B. Gower 16-Unsaturated C 19 steroids. A review of their chemistry, biochemistry and possible physiological role J. Steroid Biochem. 3 1 1972 45 103
39. B.I. Grosser, L. Monti-Bloch, C. Jennings-White, and D.L. Berliner Behavioral and electrophysiological effects of androstadienone, a human pheromone Psychoneuroendocrinology 25 3 2000 289 299 (Pubitemid 30089735)
40. 5 and P450 reductase Eur. J. Biochem./FEBS 270 6 2003 1349 1355 (Pubitemid 36384466)
41. T. Niwa, M. Fujimoto, K. Kishimoto, Y. Yabusaki, F. Ishibashi, and M. Katagiri Metabolism and interaction of bisphenol A in human hepatic cytochrome P450 and steroidogenic CYP17 Biol. Pharm. Bull. 24 9 2001 1064 1067 (Pubitemid 32894130)
42. K. Suhara, Y. Fujimura, M. Shiroo, and M. Katagiri Multiple catalytic properties of the purified and reconstituted cytochrome P-450 (P-450sccII) system of pig testis microsomes J. Biol. Chem. 259 14 1984 8729 8736 (Pubitemid 14097934)
43. G.E. Arth, A.A. Patchett, T. Jefopoulus, R.L. Bugianesi, L.H. Peterson, E.A. Ham, F.A. Kuehl Jr., and N.G. Brink Steroidal androgen biosynthesis inhibitors J. Med. Chem. 14 8 1971 675 679
44. J.J. Chart, and H. Sheppard Pharmacology and biochemistry of some amphenone analogues and other adrenal cortical inhibitors J. Med. Pharm. Chem. 1 1959 407 441
45. R. Gaunt, B.G. Steinetz, and J.J. Chart Pharmacologic alteration of steroid hormone functions Clin. Pharmacol. Ther. 9 5 1968 657 681
46. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, C.S. Higano, L.D. True, and P.S. Nelson Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res. 68 11 2008 4447 4454
47. A. Stigliano, O. Gandini, L. Cerquetti, P. Gazzaniga, S. Misiti, S. Monti, A. Gradilone, P. Falasca, M. Poggi, E. Brunetti, A.M. Agliano, and V. Toscano Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer J. Endocrinol. 194 1 2007 55 61 (Pubitemid 47162887)
48. J.B. Schenkman, D.L. Cinti, S. Orrenius, P. Moldeus, and R. Kraschnitz The nature of the reverse type I (modified type II) spectral change in liver microsomes Biochemistry 11 23 1972 4243 4251
49. H. Remmer, J. Schenkman, R.W. Estabrook, H. Sasame, J. Gillette, S. Narasimhulu, D.Y. Cooper, and O. Rosenthal Drug interaction with hepatic microsomal cytochrome Mol. Pharmacol. 2 2 1966 187 190
50. J.B. Schenkman, H. Remmer, and R.W. Estabrook Spectral studies of drug interaction with hepatic microsomal cytochrome Mol. Pharmacol. 3 2 1967 113 123
51. J.H. Dawson, L.A. Andersson, and M. Sono Spectroscopic investigations of ferric cytochrome P-450-CAM ligand complexes. Identification of the ligand trans to cysteinate in the native enzyme J. Biol. Chem. 257 7 1982 3606 3617
52. C.R. Jefcoate Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy Methods Enzymol. 52 1978 258 279
53. V.C. Njar, and A.M. Brodie Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer Curr. Pharm. Des. 5 3 1999 163 180 (Pubitemid 29159609)
54. M. Jarman, H.J. Smith, P.J. Nicholls, and C. Simons Inhibitors of enzymes of androgen biosynthesis: cytochrome P450(17) alpha and 5 alpha-steroid reductase Nat. Prod. Rep. 15 5 1998 495 512 (Pubitemid 28514543)
55. R.W. Hartmann, P.B. Ehmer, S. Haidar, M. Hector, J. Jose, C.D. Klein, S.B. Seidel, T.F. Sergejew, B.G. Wachall, G.A. Wachter, and Y. Zhuang Inhibition of CYP 17, a new strategy for the treatment of prostate cancer Arch. Pharm. (Weinheim) 335 4 2002 119 128 (Pubitemid 34728739)
56. V.M. Moreira, J.A. Salvador, T.S. Vasaitis, and V.C. Njar CYP17 inhibitors for prostate cancer treatment - an update Curr. Med. Chem. 15 9 2008 868 899 (Pubitemid 351736409)
57. C.P. Owen 17Alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review Anticancer Agents Med. Chem. 9 6 2009 613 626
58. R. DeFelice, D.G. Johnson, and J.N. Galgiani Gynecomastia with ketoconazole Antimicrobial Agents Chemother. 19 6 1981 1073 1074 (Pubitemid 11035898)
59. Y. Katz, P.C. Leung, and D.T. Armstrong Testosterone restores ovarian aromatase activity in rats treated with a 17,20-lyase inhibitor Mol. Cell. Endocrinol. 14 1 1979 37 44
60. A. Pont, P.L. Williams, S. Azhar, R.E. Reitz, C. Bochra, E.R. Smith, and D.A. Stevens Ketoconazole blocks testosterone synthesis Arch. Int. Med. 142 12 1982 2137 2140 (Pubitemid 12007067)
61. A. Pont, P.L. Williams, D.S. Loose, D. Feldman, R.E. Reitz, C. Bochra, and D.A. Stevens Ketoconazole blocks adrenal steroid synthesis Ann. Int. Med. 97 3 1982 370 372 (Pubitemid 12061586)
62. C.J. Ryan, S. Halabi, S.S. Ou, N.J. Vogelzang, P. Kantoff, and E.J. Small Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study Clin. Cancer Res. 13 7 2007 2030 2037 (Pubitemid 46649869)
63. R.J. Santen, H. Van den Bossche, J. Symoens, J. Brugmans, and R. DeCoster Site of action of low dose ketoconazole on androgen biosynthesis in men J. Clin. Endocrinol. Metab. 57 4 1983 732 736 (Pubitemid 13013529)
64. E.J. Small, A. Baron, and R. Bok Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma Cancer 80 9 1997 1755 1759 (Pubitemid 27475933)
65. E.J. Small, A.D. Baron, L. Fippin, and D. Apodaca Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal J. Urol. 157 4 1997 1204 1207 (Pubitemid 27130781)
66. E.J. Small, S. Halabi, N.A. Dawson, W.M. Stadler, B.I. Rini, J. Picus, P. Gable, F.M. Torti, E. Kaplan, and N.J. Vogelzang Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J. Clin. Oncol. 22 6 2004 1025 1033 (Pubitemid 41095034)
67. L.S. Ngo, A. Yeo, A.S. Wong, and M.H. Tay Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore Ann. Acad. Med., Singapore 36 10 2007 811 814 (Pubitemid 350119767)
68. M. Nakabayashi, W. Xie, M.M. Regan, D.M. Jackman, P.W. Kantoff, and W.K. Oh Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer Cancer 107 5 2006 975 981 (Pubitemid 44291146)
69. K. Venkatakrishnan, M. Rader, R.K. Ramanathan, S. Ramalingam, E. Chen, W. Riordan, W. Trepicchio, M. Cooper, M. Karol, L. von Moltke, R. Neuwirth, M. Egorin, and G. Chatta Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study Clin. Ther. 31 Pt 2 2009 2444 2458
70. W.P. Yong, L.Z. Wang, L.S. Tham, C.I. Wong, S.C. Lee, R. Soo, N. Sukri, H.S. Lee, and B.C. Goh A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers Cancer Chemother. Pharmacol. 62 2 2008 243 251 (Pubitemid 351692080)
71. J.R. Muindi, W.D. Yu, Y. Ma, K.L. Engler, R.X. Kong, D.L. Trump, and C.S. Johnson CYP24A1 inhibition enhances the antitumor activity of calcitriol Endocrinology 151 9 2010 4301 4312
72. W.D. Figg, S. Woo, W. Zhu, X. Chen, A.S. Ajiboye, S.M. Steinberg, D.K. Price, J.J. Wright, H.L. Parnes, P.M. Arlen, J.L. Gulley, and W.L. Dahut A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer J. Urol. 183 6 2010 2219 2226
73. M.E. Taplin, M.M. Regan, Y.J. Ko, G.J. Bubley, S.E. Duggan, L. Werner, T.M. Beer, C.W. Ryan, P. Mathew, S.M. Tu, S.R. Denmeade, W.K. Oh, O. Sartor, C.S. Mantzoros, R. Rittmaster, P.W. Kantoff, and S.P. Balk Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer Clin. Cancer Res. 15 22 2009 7099 7105
74. M.G. Rowlands, S.E. Barrie, F. Chan, J. Houghton, M. Jarman, R. McCague, and G.A. Potter Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis J. Med. Chem. 38 21 1995 4191 4197
75. G. Attard, A.H. Reid, T.A. Yap, F. Raynaud, M. Dowsett, S. Settatree, M. Barrett, C. Parker, V. Martins, E. Folkerd, J. Clark, C.S. Cooper, S.B. Kaye, D. Dearnaley, G. Lee, and J.S. de Bono Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J. Clin. Oncol. 26 28 2008 4563 4571
76. S. Haidar, P.B. Ehmer, S. Barassin, C. Batzl-Hartmann, and R.W. Hartmann Effects of novel 17alpha-hydroxylase/C17,20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo J. Steroid Biochem. Mol. Biol. 84 5 2003 555 562 (Pubitemid 36588809)
77. T.A. Yap, C.P. Carden, G. Attard, and J.S. de Bono Targeting CYP17: established and novel approaches in prostate cancer Curr. Opin. Pharmacol. 8 4 2008 449 457
78. S.E. Barrie, G.A. Potter, P.M. Goddard, B.P. Haynes, M. Dowsett, and M. Jarman Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase) J. Steroid Biochem. Mol. Biol. 50 5-6 1994 267 273 (Pubitemid 24309119)
79. F.C. Chan, G.A. Potter, S.E. Barrie, B.P. Haynes, M.G. Rowlands, J. Houghton, and M. Jarman 3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer J. Med. Chem. 39 17 1996 3319 3323 (Pubitemid 26322857)
80. D.C. Danila, M.J. Morris, J.S. de Bono, C.J. Ryan, S.R. Denmeade, M.R. Smith, M.E. Taplin, G.J. Bubley, T. Kheoh, C. Haqq, A. Molina, A. Anand, M. Koscuiszka, S.M. Larson, L.H. Schwartz, M. Fleisher, and H.I. Scher Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J. Clin. Oncol. 28 9 2010 1496 1501
81. A.H. Reid, G. Attard, D.C. Danila, N.B. Oommen, D. Olmos, P.C. Fong, L.R. Molife, J. Hunt, C. Messiou, C. Parker, D. Dearnaley, J.F. Swennenhuis, L.W. Terstappen, G. Lee, T. Kheoh, A. Molina, C.J. Ryan, E. Small, H.I. Scher, and J.S. de Bono Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J. Clin. Oncol. 28 9 2010 1489 1495
82. Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy. http://clinicaltrials.gov/ct2/show/ NCT00638690 (accessed 06.01.10).
83. Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer. http://clinicaltrials.gov/ct2/ show/NCT00887198 (accessed 06.01.10).
84. V.D. Handratta, T.S. Vasaitis, V.C. Njar, L.K. Gediya, R. Kataria, P. Chopra, D. Newman Jr., R. Farquhar, Z. Guo, Y. Qiu, and A.M. Brodie Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model J. Med. Chem. 48 8 2005 2972 2984 (Pubitemid 40552912)
85. T. Vasaitis, A. Belosay, A. Schayowitz, A. Khandelwal, P. Chopra, L.K. Gediya, Z. Guo, H.B. Fang, V.C. Njar, and A.M. Brodie Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20- lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer Mol. Cancer Ther. 7 8 2008 2348 2357
86. A. Schayowitz, G. Sabnis, V.C. Njar, and A.M. Brodie Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro Mol. Cancer Ther. 7 1 2008 121 132
87. Safety Study of TAK-700 in Subjects With Prostate Cancer. http://clinicaltrials.gov/ct2/show/NCT00569153 (accessed 07.15.10).
88. Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen. http://clinicaltrials.gov/ct2/show/NCT01046916 (accessed 15.07.10).
89. Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. http://clinicaltrials.gov/ct2/ show/NCT01084655 (accessed 09.02.10).
90. N. Matsunaga, T. Kaku, A. Ojida, T. Tanaka, T. Hara, M. Yamaoka, M. Kusaka, and A. Tasaka C(17,20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors Bioorg. Med. Chem. 12 16 2004 4313 4336 (Pubitemid 39055637)
91. N. Matsunaga, T. Kaku, A. Ojida, and A. Tasaka Synthetic studies on (1S)-1-(6,7-dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methylpropan-1-ol as a selective C17,20-lyase inhibitor Tetrahedron: Asymmetry 15 13 2004 8